Zollinger‑Ellison syndrome (gastrinoma) - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Gastrinoma) – Comprehensive Guide

Zollinger‑Ellison Syndrome (Gastrinoma) – A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (known as gastrinomas) develop in the pancreas or duodenum. The excess gastrin hormone overstimulates the stomach’s acid‑producing cells, leading to markedly high levels of gastric acid. This acid overwhelms the protective mechanisms of the gastrointestinal (GI) tract, causing severe peptic ulcers, diarrhea, and malabsorption.

  • Incidence: Approximately 1–3 cases per million people per year worldwide.[1]
  • Age: Most commonly diagnosed between ages 40–60, but can occur at any age.
  • Gender: Slight male predominance (≈55 % men).
  • Association with MEN‑1: Up to 25 % of patients have multiple endocrine neoplasia type 1, a hereditary syndrome that also predisposes to tumors of the parathyroid and pituitary glands.[2]

Symptoms

Because excess acid affects many parts of the GI tract, ZES can produce a wide spectrum of signs and symptoms. The severity often correlates with how high gastrin levels are and whether the tumor has spread.

Gastro‑intestinal manifestations

  • Peptic ulcers: Often multiple, larger than typical ulcers, and may be located in the duodenum, jejunum, or even the colon. Ulcers frequently recur despite standard ulcer therapy.
  • Abdominal pain: Burning or gnawing pain that may improve with food (duodenal ulcers) or worsen after meals (gastric ulcers).
  • Chronic diarrhea: Occurs in 40‑70 % of patients; can be watery, fatty (steatorrhea), and may lead to weight loss.
  • Nausea & vomiting: May be triggered by the high‑acid environment.
  • Gastro‑esophageal reflux disease (GERD): Heartburn and regurgitation are common because acid reflux overwhelms the lower esophageal sphincter.

Systemic / metabolic signs

  • Weight loss: Resulting from chronic diarrhea, malabsorption, and reduced appetite.
  • Fatigue & weakness: Often secondary to anemia from chronic blood loss or electrolyte disturbances (e.g., low potassium).
  • Osteoporosis: Long‑standing acid hypersecretion can impair calcium absorption.

Signs that suggest a gastrinoma

  • Refractory or recurrent ulcers despite proton‑pump inhibitor (PPI) therapy.
  • Ulcers beyond the duodenum (e.g., jejunal or colonic ulcers).
  • Secretory diarrhea (diarrhea that persists despite fasting).
  • Elevated fasting serum gastrin >1000 pg/mL (normal <100 pg/mL) with a gastric pH <2.

Causes and Risk Factors

Most gastrinomas are sporadic, but a subset is linked to genetic conditions.

Primary causes

  • Neoplastic gastrin‑producing cells: Usually arise in the duodenum (≈60 %), pancreas (≈20 %), or less commonly in lymph nodes or metastases.
  • Multiple endocrine neoplasia type 1 (MEN‑1): An inherited mutation in the MEN1 gene (encoding menin) predisposes to gastrinomas and other endocrine tumors.[3]

Risk factors

  • Family history of MEN‑1 or other endocrine tumors.
  • Known pancreatic neuroendocrine tumor (PNET) history.
  • Chronic use of proton‑pump inhibitors does not cause ZES but may mask symptoms, delaying diagnosis.

Diagnosis

Diagnosing ZES requires confirmation of hypergastrinemia, evidence of acid hypersecretion, and localization of the tumor.

Laboratory tests

  • Fasting serum gastrin level: Levels >1000 pg/mL are highly suggestive. Intermediate elevations (200–1000 pg/mL) require a secretin stimulation test.
  • Secretin stimulation test: In patients with gastrin levels 200–1000 pg/mL, an intravenous bolus of secretin paradoxically raises gastrin >120 pg/mL in ZES (versus no rise in other conditions).[4]
  • Gastric pH measurement: A pH <2 while fasting confirms acid hypersecretion.
  • Blood chemistry: CBC (to assess anemia), electrolytes (especially potassium, magnesium), vitamin B12, and calcium levels.

Imaging studies for tumor localization

  1. **Endoscopic ultrasound (EUS):** High‑resolution imaging of pancreatic head and duodenum; sensitivity 80‑90 %.
  2. **Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT:** Detects gastrinomas that express somatostatin receptors; sensitivity 85‑95 %.
  3. **Multiphasic contrast‑enhanced CT or MRI:** Helps evaluate size, local invasion, and metastasis, especially to the liver.
  4. **Selective arterial secretagogue injection (SASI) test:** Rarely used; measures gastrin gradients after gastrin‑stimulating agents injected into specific arteries.

Staging

American Joint Committee on Cancer (AJCC) TNM staging is applied once the primary tumor is identified, guiding treatment and prognosis.

Treatment Options

The therapeutic goal is twofold: control acid hypersecretion and remove or control the tumor.

Acid‑suppression therapy (initial cornerstone)

  • High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60 mg or pantoprazole 80 mg daily (often divided BID). PPIs are the most effective agents; they heal ulcers and control diarrhea.[5]
  • Histamine‑2 receptor antagonists (H2 blockers): May be added for breakthrough symptoms but are less effective than PPIs.
  • Patients typically need lifelong acid suppression, especially if tumor cannot be completely resected.

Surgical management

  • Curative resection: Preferred for localized gastrinomas (<2 cm) without metastasis. Options include duodenotomy with enucleation, pancreaticoduodenectomy (Whipple), or distal pancreatectomy, depending on tumor location.
  • Debulking surgery: For metastatic disease; removal of >90 % tumor burden can improve symptoms and may prolong survival.
  • Liver metastasis treatment: Resection, radiofrequency ablation, or hepatic arterial embolization.

Medical (non‑surgical) tumor control

  • Somatostatin analogues (Octreotide, Lanreotide): Bind somatostatin receptors, reducing gastrin release and tumor growth. Effective in both sporadic and MEN‑1‑associated gastrinomas.
  • Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive pancreatic neuroendocrine tumors, including gastrinomas.
  • Chemotherapy: Generally reserved for high‑grade or rapidly progressive disease; agents such as streptozocin, 5‑FU, or temozolomide are used.
  • Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor positive tumors; shows promise in controlling metastatic ZES.

Lifestyle & supportive measures

  • Small, frequent meals low in fat to reduce acid stimulus.
  • Stay hydrated; oral rehydration solutions may be needed for chronic diarrhea.
  • Supplement calcium and vitamin D if bone density is low.
  • Regular monitoring of gastrin levels, endoscopic surveillance for ulcer recurrence, and imaging for tumor progression.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Managing ZES is a lifelong process that combines medication adherence, monitoring, and lifestyle adjustments.

Daily medication routine

  1. Take PPIs exactly as prescribed—usually 30 minutes before a meal.
  2. If on a somatostatin analogue, note the injection schedule (monthly or every 3‑4 weeks).
  3. Use a medication diary or smartphone app to avoid missed doses.

Nutrition tips

  • Eat small, frequent meals (5–6 meals/day) to limit gastric acid spikes.
  • Limit caffeinated beverages, alcohol, and spicy foods which can aggravate acid production.
  • Include high‑protein, low‑fat foods; lean meats, dairy, legumes, and whole grains are well tolerated.
  • Consider a dietitian familiar with neuroendocrine tumors for individualized plans.

Monitoring & follow‑up

  • Serum gastrin levels every 6–12 months (or sooner if symptoms change).
  • Endoscopy every 1–2 years to evaluate ulcer healing and screen for new lesions.
  • Imaging (CT/MRI or DOTATATE PET) annually if tumor is unresectable or metastatic.
  • Bone density scan every 2–3 years if on long‑term PPIs or with low calcium intake.

Psychosocial support

Living with a rare chronic disease can be stressful. Connecting with patient advocacy groups (e.g., NEUPSI) and mental‑health professionals can improve quality of life.

Prevention

Because most gastrinomas are sporadic and not linked to modifiable behaviors, primary prevention is limited. However, the following measures can help reduce risk or detect disease earlier:

  • Genetic counseling: Individuals with a family history of MEN‑1 should undergo testing; early surveillance can catch gastrinomas before they become symptomatic.
  • Avoid unnecessary chronic PPI overuse: While PPIs do not cause ZES, indiscriminate long‑term use may mask early ulcer symptoms, delaying diagnosis.
  • Prompt evaluation of refractory ulcers or unexplained diarrhea: Early medical attention can lead to quicker diagnosis.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

  • Perforated ulcer: Can cause peritonitis—a surgical emergency.
  • Gastrointestinal bleeding: From ulcer erosion; may require endoscopic hemostasis or transfusion.
  • Severe electrolyte disturbances: Chronic diarrhea can cause hypokalemia, metabolic alkalosis, and dehydration.
  • Malnutrition & weight loss: Due to malabsorption of fats and fat‑soluble vitamins.
  • Osteoporosis/osteopenia: Chronic acid excess interferes with calcium absorption.
  • Metastatic disease: Approximately 50‑60 % of gastrinomas are malignant at diagnosis, most commonly spreading to the liver and regional lymph nodes.[6]
  • Reduced survival: Median survival for metastatic ZES is 7–9 years with modern therapies, compared with >15 years for localized disease.[7]

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • Signs of perforation: sudden sharp pain, swelling, fever, and inability to pass gas or stool.
  • Rapidly worsening diarrhea leading to dizziness, fainting, or heart palpitations (possible severe dehydration/electrolyte loss).
  • Difficulty breathing or chest pain (rare, but can occur with massive ulcer bleed).

Prompt treatment can be life‑saving.

References:

  1. Baker, M. et al. (2012). "Zollinger‑Ellison syndrome: epidemiology and clinical features." World Journal of Gastroenterology, 18(43), 6140‑6146.
  2. Mayo Clinic. (2023). "Multiple endocrine neoplasia type 1 (MEN1)." Retrieved from Mayo Clinic.
  3. CDC Genetics Home Reference. (2022). "MEN1." Retrieved from CDC.
  4. Klimstra, D. S. et al. (2005). "Secretin stimulation test in Zollinger‑Ellison syndrome." Annals of Surgery, 242(3), 407‑413.
  5. Cleveland Clinic. (2024). "Zollinger‑Ellison syndrome treatment." Retrieved from Cleveland Clinic.
  6. Mayo Clinic. (2023). "Zollinger‑Ellison syndrome." Retrieved from Mayo Clinic.
  7. Warshaw, A. L. et al. (2019). "Outcomes of surgery for pancreatic neuroendocrine tumors." Journal of the American College of Surgeons, 228(6), 1055‑1064.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References